ReCerise Therapeutics Inc. ("ReCerise"), a company committed to research and development of first-in-class therapeutics in oncology, recently entered a research partnership with the National Cancer ...

ReCerise Therapeutics Inc. ("ReCerise"), a company committed to research and development of first-in-class therapeutics in oncology, recently entered a research partnership with the National Cancer ...

Hepatocellular carcinoma continues to pose a diagnostic challenge, particularly in the setting of underlying pathomorphological changes in the liver due to cirrhosis, steatosis, or steatohepatitis.

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.